Search

Zai Lab Ltd ADR

Закрыт

СекторЗдравоохранение

18.27 0.38

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

17.95

Макс.

18.33

Ключевые показатели

By Trading Economics

Доход

-607K

-51M

Продажи

-28M

100M

Прибыль на акцию

-0.46

Рентабельность продаж

-51.215

Сотрудники

1,784

EBITDA

4.1M

-44M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+68.97% upside

Дивиденды

By Acuity

Следующий отчет о доходах

6 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-279M

2.1B

Предыдущая цена открытия

17.89

Предыдущая цена закрытия

18.27

Новостные настроения

By Acuity

100%

0%

322 / 340 Рейтинг в Healthcare

Zai Lab Ltd ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 июл. 2026 г., 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31 июл. 2026 г., 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31 июл. 2026 г., 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31 июл. 2026 г., 23:46 UTC

News

3M shares declined in after-market trading amid concerns over insider selling by EVP Kevin H. Rhodes, who sold $1.3 million worth of stock.

31 июл. 2026 г., 23:41 UTC

Social Media
News
Correlated Moves

Goldman Sachs shares declined in after-market trading amid broader market turmoil and hedge fund degrossing linked to losses on leveraged AI investments.

31 июл. 2026 г., 23:41 UTC

News

JPMorgan Chase & Co. shares are lower in after-market trading following a note highlighting ongoing market rotation and challenges from rising long-term Treasury yields.

31 июл. 2026 г., 23:36 UTC

News

Carvana shares declined in after-market trading following Citigroup's price target cut to $90, amid broader market weakness from Apple's disappointing guidance.

31 июл. 2026 г., 23:36 UTC

News

DoorDash Inc shares are lower in after-market trading amid concerns over order demand and rising fuel prices ahead of its upcoming Q2 earnings report.

31 июл. 2026 г., 23:36 UTC

News

Warner Bros Discovery shares are lower in after-market trading amid concerns over job losses tied to Paramount's $81 billion acquisition and its extended offer deadlines.

31 июл. 2026 г., 23:36 UTC

News

Bloom Energy Corp shares are lower in after-market trading amid a class action lawsuit alleging securities fraud related to its reliance on Chinese scandium.

31 июл. 2026 г., 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

31 июл. 2026 г., 23:31 UTC

News

KKR & Co Inc reported record Q2 revenue of $6.31 billion, yet shares are trading lower in after-market hours following earlier volatility.

31 июл. 2026 г., 23:26 UTC

News

Norwegian Cruise Line shares are lower in after-market hours following Citigroup's price target cut to $22 amid ongoing valuation concerns.

31 июл. 2026 г., 23:26 UTC

News

NOW Inc shares are higher after market hours, reflecting positive sentiment in the trading companies sector and ongoing demand for energy products.

31 июл. 2026 г., 23:26 UTC

News

Pomerantz LLP has filed a class action lawsuit against Verra Mobility Corp for securities fraud, contributing to lower after-market trading for the company.

31 июл. 2026 г., 23:26 UTC

News

Roblox Corp's stock is lower in after-market hours following UBS's price target cut to $45 and a class action lawsuit announcement by Pomerantz LLP.

31 июл. 2026 г., 23:16 UTC

News

KBR Inc. reported second-quarter revenue of $1.98 billion and reaffirmed full-year guidance, but shares are trading lower in after-market hours.

31 июл. 2026 г., 23:16 UTC

News

Tractor Supply Co reported second-quarter revenue of $4.54 billion, missing expectations. Shares are trading lower in after-market hours following the earnings release.

31 июл. 2026 г., 23:16 UTC

News

PBF Energy shares are lower in after-market hours following Citigroup's Neutral rating and price target increase to $74. The stock remains above its 20-day moving average.

31 июл. 2026 г., 23:16 UTC

News

Huntington Ingalls Industries shares rise in after-market trading following strong Q2 results, with sales of $3.42 billion and a non-GAAP profit of $5.27 per share.

31 июл. 2026 г., 23:16 UTC

News

Shares of GE Healthcare Technologies are lower in after-market trading following UBS's Neutral rating and a price target increase to $73.

31 июл. 2026 г., 23:16 UTC

News

Gilead Sciences shares are higher in after-market trading amid market fluctuations. Accessibility challenges for lenacapavir in Latin America may impact potential sales.

31 июл. 2026 г., 23:16 UTC

News

Alnylam Pharmaceuticals reported Q2 2026 net product revenue of $1.2 billion, driven by strong AMVUTTRA uptake. Shares rose slightly in after-market trading.

31 июл. 2026 г., 23:11 UTC

News

Lockheed Martin secured a $107.29 million Navy contract for VH-92A rotor blades, with shares trading higher in after-market hours.

31 июл. 2026 г., 23:06 UTC

News

Hawaiian Electric Industries has signed a 30-year power purchase agreement, with shares trading higher in after-market hours.

31 июл. 2026 г., 23:06 UTC

News

General Electric Co shares are lower in after-market trading, despite recent analyst upgrades and reaffirmed buy ratings for GE Aerospace.

31 июл. 2026 г., 23:06 UTC

News

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

31 июл. 2026 г., 23:06 UTC

News

Permian Resources Corp shares are trading higher in after-market hours following recognition as a top investment choice by Yahoo Finance, citing strong financial performance.

31 июл. 2026 г., 23:06 UTC

Social Media
News

NVIDIA shares are lower in after-market trading despite strong fiscal first-quarter results, with revenues of $81.6 billion and record data center sales.

31 июл. 2026 г., 23:06 UTC

News

Coinbase Global reported a record share of global crypto trading volume but also a significant net loss. Shares are roughly flat in after-market trading.

Сравнение c конкурентами

Изменение цены

Zai Lab Ltd ADR Прогноз

Целевая цена

By TipRanks

68.97% рост

Прогноз на 12 месяцев

Средняя 30.87 USD  68.97%

Максимум 44 USD

Минимум 21.6 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Zai Lab Ltd ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

3 ratings

2

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

322 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat